The funding will help support the Ontario Provincial ALS Program to meet the needs of the roughly 1,300 people in Ontario ...

Columnist Kristin Neva and her husband with ALS are sometimes asked about the way they went about building their accessible home.

Leal Therapeutics raised $45 million for drug development, including advancing a promising therapy into clinical trials for ...

Drinking straws are one of the tools in columnist Dagmar Munn's arsenal to combat dysphagia while living with ALS.

Biotech company Auttx has received a $125,000 grant to advance the development of new molecules that aim to restore normal RNA processing in people with amyotrophic lateral sclerosis (ALS), ...

Altered activity of ancient viral genes were linked to neurodegenerative diseases including ALS in a recent analysis.

Avicenna received a patent covering ROCK inhibitor compounds for ALS, Parkinson’s, and other neurodegenerative conditions.

What is NurOwn for ALS? NurOwn (debamestrocel) is an investigational cell-based therapy designed to slow disease progression and potentially extend survival in people with amyotrophic lateral ...

This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other present or future content posted by the contributor, not expressly ...

Long-term treatment with the cell therapy NurOwn was found to significantly extend survival for ALS patients compared with ...